Pay in 4 interest-free payments of $7.28 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
ClinicalTrials.gov: NCT07567001 (HF-POLARIS) | Mechanism: GLP-1 / amylin dual agonist TRIAL SPOTLIGHT Educational spotlight selected by editors Semaglutide Without the Needle: A Dissolving Microarray Patch Enters the Clinic Terrestrial Bio (formerly Vaxess Technologies) dosed the first patients on July 1, 2026, in a Phase 1 trial (NCT07673900) evaluating VX-201, a needle-free microarray patch branded as Tacterra that delivers the established GLP-1 receptor agonist semaglutide
The sublingual data is from clinical observation
Slowing the pace of weight loss when possible and working closely with your healthcare provider can also help reduce unnecessary strain on the body
Your doctor may occasionally change your dose
US$ 28.70
US$ 25.30
US$ 22.59
US$ 27.68
![Lu Meng, Wu General [Portal Three Kingdoms] Eternal Masters](https://cdn.shopify.com/s/files/1/0266/9513/9533/files/1e9c251f-5166-513a-bfcc-292eb5d2b2ed.jpg?v=1776224267)